April 25-30, 2025, American Association for Cancer Research

1)Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers.

2)Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity.

3)Discovery and preclinical characterization of novel macrocyclic KIF18A inhibitors for treatment of chromosomally instable tumors.

4)Development of a Differentiated, Best-in-Class oral Cbl-b inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy.